Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$4.83
▲ $0.08 (+1.7%)
Market data updated: 09/22 06:40 AM
Fundamentals updated: 09/22/2026
News analyzed: 09/22/2026
Market Cap
$15.54M
Day Range
$4.67 - $4.83
52-Week Range
$3.29 - $20.00
Beta
—
Next Earnings
09.11.2026
Support
$4.25
Resistance
$5.36
PASG is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-32.6% (1Y)
Strengths: 13/21 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 31.8%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 5.7% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
58
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
66
Quality
No data available
Value
55
Momentum
72
Risk
40
Sentiment
50
Fundamental
46
Institutional
25
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Passage Bio has centered on its financial struggles and a major corporate shift. The company reported improved but still substantial quarterly losses of $2.44 per share in Q2, outperforming analyst expectations. More prominently, Passage Bio announced a merger with Remix Therapeutics in June, structured as an all-stock deal, which led to a sharp 16% stock decline after hours. Analysts debated whether the merger could unlock value or if the company’s financial trajectory remains uncertain.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Passage Bio, Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 2 vs. 2 out of the last 8 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
13
🎯 Conviction (vs. Emotion)
50
Psychology
50
Fundamentals
46
Technical
72
Valuation
55
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
-21%
Market Narrative
50
Fundamental Reality
50
Narrative Gap
+0
🧠 StockIQ Psychologist
The market behavior suggests herding dominates, with participants aligning moves closely to peers despite modest FOMO and loss aversion signals. Overconfidence hints at isolated optimism, but neutral RSI and sentiment dampen euphoria. The key question is whether the narrative gap (-2) reflects underappreciated fundamentals or if traders are simply following peers into a synchronized pullback. Low volume and ATR suggest no panic, but the 3-month decline may keep loss aversion latent. The open question: *Will the gap widen if fundamentals improve, or will traders exit en masse if peers diverge?*
Updated: 09/06/2026, 05:13 PM
What could change this?
👥 What the crowd believes
"PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?"
"Remix to go public in reverse merger with once high-flying Passage Bio"
"reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47)"
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 91/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The scores for PASG span the full range, from a perfect 100 to a zero, reflecting how the underlying doctrines diverge. Based on Graham’s documented principles, the model estimates the stock to be attractive for both defensive (score 88) and enterprising (score 87) value investors, while Lynch’s model flags insufficient growth data for a definitive read. Marks and Bagehot assign moderate scores (72‑75), emphasizing reasonable risk pricing, liquidity and a non‑overextended cycle, whereas Schwager, Fisher and Livermore register middling to low scores, indicating no clear edge or trend. Loeb, Nelson, Smith, Veblen and Housel give the lowest scores (15‑0), highlighting capital‑risk concerns, overbought conditions, lack of dividend/growth information, speculative growth motives and volatility. Consequently, value‑oriented methodologies tend toward a favorable view of PASG, while momentum, growth and market‑efficiency frameworks remain skeptical.
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 91
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 88
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 88
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 85
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 75
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 72
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 53
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jack Schwager
Market Wizards (1989)
🟡 47
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 42
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 37
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 31
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 283 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A pattern consistent with an early/mid accumulation phase — a trading range after a decline with declining volume.
Medium confidence
$4.25
Range Bottom
$5.36
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-242.7%
ROA
-73.1%
ROIC
—
EPS
-$14.35
Cash
$46.30M
Total Debt
—
Current Ratio
2.07
Debt/Equity
—
אין נתונים היסטוריים זמינים.
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$5.91
Tangible Book Value per Share (Tangible NAV)
$5.91
Sentiment based on basic keywords (not AI) — 2 positive, 4 neutral, 2 negative out of the last 8 articles.
Benzinga · 10.8.2026
MT Newswires · 25.6.2026
BioPharma Dive · 25.6.2026
Stocktwits · 24.6.2026
Stocktwits · 24.6.2026
MT Newswires · 24.6.2026
GlobeNewswire · 24.6.2026
Insider Monkey · 20.5.2026
Passage Bio, Inc. (PASG) currently has a StockIQ AI score of 58/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PASG currently scores 58/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
PASG's technical score is 72/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 31.8%; Net income growth: 29.7%; Current ratio: 2.07.
Based on the real signals StockIQ computed: ATR: 5.7% of price; Calmar: -0.33 (3y annualized return -29.0% / max drawdown 88.2%); Return on equity (ROE): -242.7% (negative).
StockIQ has no recorded dividend payment history for PASG.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 1 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | Open Market Purchase | 25.6.2026 | 50,055 | +50,055 | $4.12 |
| Countouriotis Athena | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Sondhi Dolan | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Kapadia Sandip | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Kassberg Thomas Richard | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| GOWEN MAXINE | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Porter Derrell | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| GOWEN MAXINE | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Kassberg Thomas Richard | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Countouriotis Athena | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Kapadia Sandip | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Porter Derrell | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Sondhi Dolan | Grant/Award from Employer | 19.5.2026 | 10,539 | +10,539 | — |
| Chou William | Grant/Award from Employer | 16.3.2026 | 58,000 | +58,000 | — |
| Borthwick Kathleen | Grant/Award from Employer | 16.3.2026 | 15,610 | +15,610 | — |
| Borthwick Kathleen | Grant/Award from Employer | 16.3.2026 | 15,610 | +15,610 | — |
| Chou William | Grant/Award from Employer | 16.3.2026 | 58,000 | +58,000 | — |
| Borthwick Kathleen | Exercise of Derivative Securities | 8.1.2026 | 5,000 | -5,000 | — |
| Chou William | Open Market Sale | 8.1.2026 | 4,076 | -4,076 | $18.44 |
| Chou William | Exercise of Derivative Securities | 8.1.2026 | 10,000 | -10,000 | — |
| Chou William | Exercise of Derivative Securities | 8.1.2026 | 10,000 | +10,000 | — |
| Borthwick Kathleen | Exercise of Derivative Securities | 8.1.2026 | 5,000 | +5,000 | — |
| Borthwick Kathleen | Open Market Sale | 8.1.2026 | 2,062 | -2,062 | $18.44 |
| Chou William | Exercise of Derivative Securities | 8.1.2026 | 10,600 | +10,000 | — |
| Chou William | Open Market Sale | 8.1.2026 | 6,524 | -4,076 | $18.44 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
101,638 shares short as of 2026-08-31 · vs. 155,837 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
33.7% of trading volume this week was short selling, vs. 37.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology